Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
1. A composition comprising an oligonucleotide that targets Angiopoietin like 4 (ANGPTL4) and when administered to a cell decreases expression of ANGPTL4; wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises an oligonucleotide sequence of any of SEQ ID NOS: 13971-13973 or 13975-13977 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of any of 13971-13973 or 13975-13977 in which at least one internucleoside linkage is modified and at least one nucleoside is modified; and wherein the antisense strand comprises an oligonucleotide sequence of any of SEQ ID NOS: 13979-13981 or 13983-13985 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of any of SEQ ID NOS: 13979-13981 or 13983-13985 in which at least one internucleoside linkage is modified and at least one nucleoside is modified.
2. The composition of claim 1 , wherein the at least one nucleoside is modified comprises a 2′-fluoro modified nucleoside.
3. The composition of claim 1 , wherein the at least one nucleoside is modified comprises a 2′-O-methyl modified nucleoside.
4. The composition of claim 1 , wherein the oligonucleotide comprises 15-23 modified nucleosides.
5. The composition of claim 4 , wherein the 15-23 modified nucleosides comprises 2′-fluoro modified nucleosides and 2′-O-methyl modified nucleosides.
6. The composition of claim 1 , wherein the at least one internucleoside linkage is modified comprises a phosphorothioate linkage.
7. The composition of claim 1 , wherein the oligonucleotide comprises a GalNAc ligand attached to the oligonucleotide.
8. The composition of claim 7 , wherein the GalNAc ligand comprises 3 GalNAc moieties.
9. The composition of claim 7 , wherein the GalNAc ligand attached to the oligonucleotide comprises a GalNAc ligand attached at a 5′ or 3′ terminus of the sense strand.
10. The composition of claim 1 , wherein the antisense strand comprises the nucleoside sequence of any of SEQ ID NOS: 13979-13981 or 13983-13985, and wherein the sense strand comprises the nucleoside sequence of any of SEQ ID NOS: 13971-13973 or 13975-13977.
11. The composition of claim 1 , wherein the sense strand or the antisense strand comprises a 3′ overhang.
12. A composition comprising an oligonucleotide that targets Angiopoietin like 4 (ANGPTL4) and when administered to a cell decreases expression of ANGPTL4; wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises an oligonucleotide sequence of any of SEQ ID NOS: 13970-13977 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of any of SEQ ID NOS: 13970-13977 in which at least one internucleoside linkage is modified and at least one nucleoside is modified; wherein the antisense strand comprises an oligonucleotide sequence of any of SEQ ID NOS: 13978-13985 in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of any of SEQ ID NOS: 13978-13985 in which at least one internucleoside linkage is modified and at least one nucleoside is modified; and
wherein the sense strand or the antisense strand comprises one of the following modification patterns: 5′-NfsnsNfnNfnNfNfNfnNfnNfnNfnNfnNfsnsn-3′ (SEQ ID NO: 13954), 5′-nsnsnnNfnNfNfNfnnnnnnnnnnsnsn-3′ (SEQ ID NO: 13955), 5′-nsnsnnNfnNfnNfnnnnnnnnnnsnsn-3′ (SEQ ID NO: 13956), 5′-NfsnsNfnNfnNfNfNfnNfnNfnNfnNfnNfsnsnN-3′ (SEQ ID NO: 13957), 5′-nsnsnnNfnNfNfNfnnnnnnnnnnsnsnN-3′ (SEQ ID NO: 13958), 5′-NfsnsNfnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3′ (SEQ ID NO: 13959), 5′-nsNfsnNfnNfnNfnNfnnnNfnNfnNfnsnsn-3′ (SEQ ID NO: 13960), 5′-nsNfsnnnNfnNfNfnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13961), 5′-nsNfsnnnNfnnnnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13962), 5′-nsNfsnNfnNfnnnnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13963), 5′-nsNfsnnnNfnNfnnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13964), 5′-nsNfsnNfnNfnNfnNfnNfnNfnNfnNfnsnsn-3′ (SEQ ID NO: 13965), 5′-nsNfsnNfnNfnNfNfnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13966), 5′-nsNfsnnnnnnnnnnnNfnnnnnsnsn-3′ (SEQ ID NO: 13967), or 5′-nsNfsnnnNfnnnnnnnNfnNfnNfnsnsn-3′ (SEQ ID NO: 13968), wherein “N” comprises one or more nucleosides, “Nf” is a 2′ fluoro-modified nucleoside, “n” is a 2′ O-methyl modified nucleoside, and “s” is a phosphorothioate linkage.
13. The composition of claim 1 , wherein the sense strand comprises the nucleoside sequence of any of SEQ ID NOS: 13973 or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions; and wherein the antisense strand comprises the nucleoside sequence of SEQ ID NO: 13981 or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions.
14. The composition of claim 1 , wherein the sense strand comprises the nucleoside sequence of SEQ ID NO: 13977, and wherein the antisense strand comprises the nucleoside sequence of SEQ ID NO: 13985.
15. The composition of claim 14 , wherein the sense strand comprises modification pattern 2S: 5′-nsnsnnNfnNfNfNfnnnnnnnnnnsnsn-3′ (SEQ ID NO: 13955), and wherein the antisense strand comprises modification pattern 3AS: 5′-nsNfsnnnNfnnnnnnnNfnNfnnnsnsn-3′ (SEQ ID NO: 13962), wherein “Nf” is a 2′ fluoro-modified nucleoside, “n” is a 2′ O-methyl modified nucleoside, and “s” is a phosphorothioate linkage.
16. The composition of claim 15 , wherein the oligonucleotide comprises a GalNAc ligand attached at a 3′ end of the sense strand.
17. The composition of claim 14 , wherein the sense strand comprises modification pattern 6S: 5′-NfsnsNfnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3′ (SEQ ID NO: 13959), wherein “Nf” is a 2′ fluoro-modified nucleoside, “n” is a 2′ O-methyl modified nucleoside, and “s” is a phosphorothioate linkage.
18. The composition of claim 17 , wherein the oligonucleotide comprises a GalNAc ligand attached at a 5′ end of the sense strand.
19. The composition of claim 17 , wherein the oligonucleotide comprises a GalNAc ligand attached at a 3′ end of the sense strand.
20. The composition of claim 17 , wherein the antisense strand comprises modification pattern 6AS: 5′-nsNfsnNfnNfnNfnNfnNfnNfnNfnNfnsnsn-3′ (SEQ ID NO: 13965), or 8AS: 5′-nsNfsnnnnnnnnnnnNfnnnnnsnsn-3′ (SEQ ID NO: 13967), wherein “Nf” is a 2′ fluoro-modified nucleoside, “n” is a 2′ O-methyl modified nucleoside, and “s” is a phosphorothioate linkage.